Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Tom Woiwode
AddedApr 2, 2024
UpdatedMay 31, 2026
Tom Woiwode

Tom Woiwode

Board Member, Tempest Therapeutics

Crunchbase

Tom Woiwode's Career

Tempest Therapeutics
Tempest Therapeutics

South San Francisco, CA, US

Board Member· Board
Gritstone bio
Gritstone bio

Emeryville, CA, US

Board Member· Board
Coda Biotherapeutics
Coda Biotherapeutics

South San Francisco, CA, US

Board Member· Board
Vividion Therapeutics
Vividion Therapeutics

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Tom Woiwode's Career

Tempest Therapeutics
Tempest Therapeutics
Acquired$90M02011South San Francisco, CA, US
Board Member· Board

Leadership at Tempest Therapeutics

Bradley BolzonBradley BolzonBoard Member
Ronit SimantovRonit SimantovBoard Member
Christine PellizzariChristine PellizzariBoard Member
Geoff NicholGeoff NicholBoard Member
Robert WeisskoffRobert WeisskoffBoard Member
Michael RaabMichael RaabBoard Member

Similar to Tempest Therapeutics

PineTree TherapeuticsPineTree TherapeuticsCambridge, MA, USBiotech Therapiesest. 2019PineTree TherapeuticsCambridge, MA, US · est. 2019

PineTree Therapeutics: Innovating biotech therapies in Oncology and Immuno-oncology.

Series B · $23.5M17
Terpenoid TherapeuticsTerpenoid TherapeuticsCoralville, IA, USDrug Developmentest. 2005Terpenoid TherapeuticsCoralville, IA, US · est. 2005

Terpenoid Therapeutics Inc: Innovating cancer cure through biotech-driven drug discovery and development.

Pre-Seed · $1M30
Window TherapeuticsWindow TherapeuticsBoston, MA, USCancer Treatmentest. 2021Window TherapeuticsBoston, MA, US · est. 2021

Window Therapeutics: A biotech firm innovating targeted cancer treatments for unmet patient needs.

Angel · $256k4
Fuse BiotherapeuticsFuse BiotherapeuticsLos Angeles, CA, USTherapeuticsest. 2021Fuse BiotherapeuticsLos Angeles, CA, US · est. 2021

FuseBio: Innovating immune-modulating therapeutics for cancer treatment.

Seed · $9.5M5
Gritstone bio
Gritstone bio
Public$571.6M2332015Emeryville, CA, US
Board Member· Board

Leadership at Gritstone bio

Steve KrognesSteve KrognesBoard Member
Mark CobboldMark CobboldCo-Founder
Shefali AgarwalShefali AgarwalBoard Member
Andrew R. AllenAndrew R. AllenBoard Member
Elaine V. JonesElaine V. JonesBoard Member

Similar to Gritstone bio

Grit BioGrit BioNew York City, NY, USCancer Treatmentsest. 2017Grit BioNew York City, NY, US · est. 2017

Grit Bio: NY-based innovator of safer cancer treatments, specializing in pharyngeal carcinoma since 2017.

Angel · $256k6
GRAILGRAILMenlo Park, CA, USCancer Detectionest. 2016GRAILMenlo Park, CA, US · est. 2016

GRAIL, Inc., a Menlo Park-based biotech firm, specializes in early cancer detection using science and technology.

Public · $2B823
INmune BioINmune BioBoca Raton, FL, USCancer Treatmentsest. 2015INmune BioBoca Raton, FL, US · est. 2015

INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.

Public · $103.2M17
Iovance BiotherapeuticsIovance BiotherapeuticsSan Carlos, CA, USCancer Therapiesest. 2007Iovance BiotherapeuticsSan Carlos, CA, US · est. 2007

Iovance Biotherapeutics: A California-based biotech firm specializing in novel cancer immunotherapies.

Public503
Coda Biotherapeutics
Coda Biotherapeutics
Series D$62.7M292014South San Francisco, CA, US
Board Member· Board

Leadership at Coda Biotherapeutics

Michael NarachiMichael NarachiBoard Member
Kenneth GreenbergKenneth GreenbergCo-Founder
Mitchell H. FinerMitchell H. FinerCo-Founder
Joseph GloriosoJoseph GloriosoCo-Founder
Nicholas BoulisNicholas BoulisCo-Founder
Mitch FinerMitch FinerBoard Member
Vividion Therapeutics
Vividion Therapeutics
Acquired$371.5M02013San Diego, CA, US
Board Member· Board

Leadership at Vividion Therapeutics

John ClarkeJohn ClarkeBoard Member
Phil BaranPhil BaranCo-Founder
Paul SchimmelPaul SchimmelBoard Member
Jin-Quan YuJin-Quan YuCo-Founder
Aleksandra RizoAleksandra RizoBoard Member
Benjamin CravattBenjamin CravattCo-Founder

Tom Woiwode's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Tom Woiwode

Ash KhannaAsh KhannaBoard Member · Pivotal bioVenture PartnersCary PfefferCary PfefferBoard Member · Tango TherapeuticsChris WilfongChris WilfongCo-Founder · 76BioSean Wuxiong CaoSean Wuxiong CaoBoard Member · Ensem TherapeuticsBill BaumBill BaumBoard Member · GevoEli ThomssenEli ThomssenFounder · Axenic Dental